Literature DB >> 10376872

A nested double pseudoknot is required for self-cleavage activity of both the genomic and antigenomic hepatitis delta virus ribozymes.

T S Wadkins1, A T Perrotta, A R Ferré-D'Amaré, J A Doudna, M D Been.   

Abstract

The crystal structure of a genomic hepatitis delta virus (HDV) ribozyme 3' cleavage product predicts the existence of a 2 bp duplex, P1.1, that had not been previously identified in the HDV ribozymes. P1.1 consists of two canonical C-G base pairs stacked beneath the G.U wobble pair at the cleavage site and would appear to pull together critical structural elements of the ribozyme. P1.1 is the second stem of a second pseudoknot in the ribozyme, making the overall fold of the ribozyme a nested double pseudoknot. Sequence comparison suggests the potential for P1.1 and a similar fold in the antigenomic ribozyme. In this study, the base pairing requirements of P1.1 for cleavage activity were tested in both the genomic and antigenomic HDV ribozymes by mutagenesis. In both sequences, cleavage activity was severely reduced when mismatches were introduced into P1.1, but restored when alternative base pairing combinations were incorporated. Thus, P1.1 is an essential structural element required for cleavage of both the genomic and antigenomic HDV ribozymes and the model for the antigenomic ribozyme secondary structure should also be modified to include P1.1.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10376872      PMCID: PMC1369799          DOI: 10.1017/s1355838299990209

Source DB:  PubMed          Journal:  RNA        ISSN: 1355-8382            Impact factor:   4.942


  35 in total

1.  The crystal structure of an all-RNA hammerhead ribozyme: a proposed mechanism for RNA catalytic cleavage.

Authors:  W G Scott; J T Finch; A Klug
Journal:  Cell       Date:  1995-06-30       Impact factor: 41.582

2.  Crystal structure of a hepatitis delta virus ribozyme.

Authors:  A R Ferré-D'Amaré; K Zhou; J A Doudna
Journal:  Nature       Date:  1998-10-08       Impact factor: 49.962

3.  The hepatitis delta (delta) virus possesses a circular RNA.

Authors:  A Kos; R Dijkema; A C Arnberg; P H van der Meide; H Schellekens
Journal:  Nature       Date:  1986 Oct 9-15       Impact factor: 49.962

Review 4.  The molecular biology of hepatitis delta virus.

Authors:  M M Lai
Journal:  Annu Rev Biochem       Date:  1995       Impact factor: 23.643

5.  Chemical probing studies of variants of the genomic hepatitis delta virus ribozyme by primer extension analysis.

Authors:  P K Kumar; K Taira; S Nishikawa
Journal:  Biochemistry       Date:  1994-01-18       Impact factor: 3.162

6.  Three-dimensional structure of a hammerhead ribozyme.

Authors:  H W Pley; K M Flaherty; D B McKay
Journal:  Nature       Date:  1994-11-03       Impact factor: 49.962

7.  Cloning and expression of the gene for bacteriophage T7 RNA polymerase.

Authors:  P Davanloo; A H Rosenberg; J J Dunn; F W Studier
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

8.  A new principle of RNA folding based on pseudoknotting.

Authors:  C W Pleij; K Rietveld; L Bosch
Journal:  Nucleic Acids Res       Date:  1985-03-11       Impact factor: 16.971

9.  Structure, sequence and expression of the hepatitis delta (delta) viral genome.

Authors:  K S Wang; Q L Choo; A J Weiner; J H Ou; R C Najarian; R M Thayer; G T Mullenbach; K J Denniston; J L Gerin; M Houghton
Journal:  Nature       Date:  1986 Oct 9-15       Impact factor: 49.962

10.  Optimal self-cleavage activity of the hepatitis delta virus RNA is dependent on a homopurine base pair in the ribozyme core.

Authors:  M D Been; A T Perrotta
Journal:  RNA       Date:  1995-12       Impact factor: 4.942

View more
  36 in total

1.  Ribozyme cleavage of a 2,5-phosphodiester linkage: mechanism and a restricted divalent metal-ion requirement.

Authors:  I H Shih; M D Been
Journal:  RNA       Date:  1999-09       Impact factor: 4.942

2.  A host-specific function is required for ligation of a wide variety of ribozyme-processed RNAs.

Authors:  C E Reid; D W Lazinski
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

3.  Delta ribozyme benefits from a good stability in vitro that becomes outstanding in vivo.

Authors:  Dominique Lévesque; Sanaa Choufani; Jean-Pierre Perreault
Journal:  RNA       Date:  2002-04       Impact factor: 4.942

4.  Ribozyme-based gene-inactivation systems require a fine comprehension of their substrate specificities; the case of delta ribozyme.

Authors:  Lucien Junior Bergeron; Jonathan Ouellet; Jean-Pierre Perreault
Journal:  Curr Med Chem       Date:  2003-12       Impact factor: 4.530

5.  Activity of HDV ribozymes to trans-cleave HCV RNA.

Authors:  Yue-Cheng Yu; Qing Mao; Chang-Hai Gu; Qi-Fen Li; Yu-Ming Wang
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

6.  Cross-linking experiments reveal the presence of novel structural features between a hepatitis delta virus ribozyme and its substrate.

Authors:  Jonathan Ouellet; Jean-Pierre Perreault
Journal:  RNA       Date:  2004-07       Impact factor: 4.942

7.  Long-distance communication in the HDV ribozyme: insights from molecular dynamics and experiments.

Authors:  Narayanan Veeraraghavan; Philip C Bevilacqua; Sharon Hammes-Schiffer
Journal:  J Mol Biol       Date:  2010-07-17       Impact factor: 5.469

8.  Gene targeting in the Gram-Positive bacterium Lactococcus lactis, using various delta ribozymes.

Authors:  Karine Fiola; Jean-Pierre Perreault; Benoit Cousineau
Journal:  Appl Environ Microbiol       Date:  2006-01       Impact factor: 4.792

9.  Chemical rescue, multiple ionizable groups, and general acid-base catalysis in the HDV genomic ribozyme.

Authors:  Anne T Perrotta; Timothy S Wadkins; Michael D Been
Journal:  RNA       Date:  2006-05-11       Impact factor: 4.942

10.  Examination of the folding pathway of the antigenomic hepatitis delta virus ribozyme reveals key interactions of the L3 loop.

Authors:  Cédric Reymond; Jonathan Ouellet; Martin Bisaillon; Jean-Pierre Perreault
Journal:  RNA       Date:  2006-11-14       Impact factor: 4.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.